Trial
NCT04825223
Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Sanofi Pasteur, a Sanofi Company
Collaborators
—
Condition
Meningococcal Immunisation
Intervention
Multicomponent Meningococcal B Vaccine
Why stopped
Sponsor decision. Termination decision not related to any safety concern.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-10